DexCom stock rallies and outperforms Abbott and Insulet

7 articles · Updated · MarketWatch · May 6

Shares rose 1.48% to $60.36 on Wednesday, snapping a two-day losing streak as the S&P 500 gained 1.46% and the Dow added 1.24%.
DexCom beat rivals as Abbott Laboratories fell 1.00% to $86.30 and Insulet dropped 9.70% to $151.28.
Trading volume reached 5.9 million shares, above its 50-day average of 4.3 million, though the stock remains 32.92% below its 52-week high of $89.98.

With rivals facing lawsuits and recalls, can DexCom's new OTC device cement its market dominance?

As science moves closer to a diabetes cure, what is the long-term future for diabetes management tech?

Will over-the-counter glucose monitors empower wellness consumers or create a new wave of health anxiety?